PDS Biotechnology (PDSB) Profit After Tax (2014 - 2026)

PDS Biotechnology (PDSB) has 12 years of Profit After Tax data on file, last reported at -$7.6 million in Q4 2025.

• Quarterly Profit After Tax rose 4.9% year-over-year to -$7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$34.5 million (up 8.28% YoY) and the FY2025 annual result came in at -$34.5 million, up 8.28% from the prior year.
• Profit After Tax grew to -$7.6 million in Q4 2025, from -$9.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$588931.0 in Q2 2021 to a low of -$19.1 million in Q4 2022.
• A 5-year average of -$8.6 million and a median of -$8.5 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2021 — Profit After Tax jumped 79.9% — and 2022, when it sank 888.1%.
• Tracing PDSB's Profit After Tax over 5 years: stood at -$6.3 million in 2021, then slumped by 202.81% to -$19.1 million in 2022, then soared by 43.05% to -$10.9 million in 2023, then gained by 27.03% to -$8.0 million in 2024, then grew by 4.9% to -$7.6 million in 2025.
• The last three Profit After Tax figures came in at -$7.6 million (Q4 2025), -$9.0 million (Q3 2025), and -$9.4 million (Q2 2025), per Business Quant data.